Agonistas do receptor GLP-1: novas fronteiras e desafios
GLP-1 Blog Series: Introduction
Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public a quick fix and a path to losing excess weight or resolving their diabetic issues.
Recently, a new class of drugs, based on GLP-1, are revolutionizing medicine and the treatment of patients with diabetes, obesity, and other disorders associated with obesity. GLP-1 is a short-acting hormone that is released after eating. This hormone helps regulate glucose levels in the body by causing the pancreas to release insulin, which lowers sugar levels in the blood. Furthermore, the hormone causes individuals to feel full by both causing the gut to reduce how quickly it processes food and acting on different parts of the brain which control hunger and satiety.
GLP-1 receptor agonists are a new class of drugs which mimic the activity of GLP-1 and maintain the benefits of the GLP-1 hormone in patients. The U.S. Food & Drug Administration (FDA) has approved many drugs in this class over the past couple of years including Ozempic, Wegovy, Mounjaro, and Zepbound to name a few. These drugs are approved to treat different conditions, including obesity and type 2 diabetes, and are now being tested for treatments far beyond obesity and diabetes. Studies to treat cardiovascular disease, addictive behavior, and rheumatologic diseases are just a few of the ongoing trials. Together, this new class of drugs could lead to sales in the tens of billions of dollars in the upcoming years.
A rápida expansão desta área tecnológica levanta muitas questões comerciais e jurídicas. Iremos explorar muitas delas ao longo dos próximos artigos desta série. Estes tópicos incluem:
- Issues related to deals and licensing for GLP-1 therapeutics
- Patent/IP challenges to consider for GLP-1 therapeutics
- Clinical trial issues for GLP-1 therapeutics
- FDA/regulatory issues for GLP-1 therapeutics
- Litigation issues for GLP-1 therapeutics
For additional resources on GLP-1 Drugs and how they will change the health care & life sciences and technology industries, click here to read the other articles in our series.
A Foley está aqui para ajudá-lo a lidar com os impactos de curto e longo prazo decorrentes das mudanças regulatórias. Temos os recursos para ajudá-lo a navegar por essas e outras considerações jurídicas importantes relacionadas às operações comerciais e questões específicas do setor. Entre em contacto com os autores, o seu parceiro de relacionamento da Foley, o nosso Setor de Saúde e Ciências da Vidaou ao nosso Setor de Tecnologia Inovadora em caso de dúvidas.